What should I know about Zoldenrasib clinical trials?

Zoldenrasib is a newer KRAS G12C inhibitor being studied in clinical trials for non-small cell lung cancer, particularly for patients whose tumors have this specific mutation. Clinical trials can offer access to promising new treatments, and speaking with your oncology team about whether this might be a suitable option based on your specific situation and tumor characteristics would be the best next step to get personalized guidance.